Navigation Links
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Date:9/16/2009

BERLIN, Sept. 17 /PRNewswire/ -- Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

"Bayer is committed to discovering and developing innovative cancer-fighting therapies, and as a global organization with widespread reach and impact, we are able to apply our experience, knowledge and passion to offer treatments that may make life better for cancer patients across the globe," said Rob Rosen, Head of the Therapeutic Area Oncology at Bayer HealthCare. "While much progress has been made in the treatment of cancer, there is still an unmet medical need for improved therapies that may help patients manage their disease, ultimately treating cancer as a chronic illness, rather than a devastating disease."

Nexavar Data Highlights

Nexavar is currently approved in more than 80 countries for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer, and in more than 90 countries for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer. Even though these indications are well established, the utility of Nexavar continues to be evaluated in these tumor types, with ongoing studies examining special patient populations and long-term use. Data on these indications being presented at ECCO-ESMO include results from two Phase III studies evaluating Nexavar in HCC and six studies examining Nexavar in RCC.

In addition to its current indications, Nexavar continues to be evaluated as a single agent or combination treatment in a wide range of cancers, including
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
2. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
3. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
4. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
5. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
9. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Bayer Issues Additional Guidance to Physicians on Trasylol(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...20 BD (Becton, Dickinson...ompletion of its acquisition of HandyLab, Inc., an...nd manufactures molecular diagnostic assays and au...yLab announced an exclusive agreement for BD to de...ndyLab Jaguar(TM) platform, the first fully integr...
(Date:11/19/2009)...wswire/ -- In response to an ever-increasing numbe...cines, Operation Pangea II, involving 24 countries... Organization,s International Medical Products Ant...he dangers of buying medicines online. ,, The w... arrests and the seizure of thousands of potential...
(Date:11/19/2009)... The D e al magazine...t Admired Corporate Dealmakers for the second cons...st Admired Dealmaker in pharma/biotech for the mos...stitures since January 2006. ,, Over the past d...with a focus on high-growth, innovation-driven bus...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference 5600 1Babies Injured in Car Seats Used Outside of Cars 59817 1Babies Injured in Car Seats Used Outside of Cars 59817 2Babies Injured in Car Seats Used Outside of Cars 59817 3Henk Stunnenbergs lab applies Genomatix NextGen sequencing data analysis 59814 1
...sults add to body of clinical evidence demonstrati...ings for treatment of stress urinary ...J., Sept. 8 A new study published in the,August i...es data of an,11-year follow up study on the safet...TVT) as a treatment for stress urinary incontinenc...
...arah Palin" and "Dr. Siegal,s Cookie Diet" Were th... 2008; "John McCain" Rounded Out the Top 5, MCLEA...ine and retail distributor of Dr. Siegal,s COOKIE ...that on Friday, August 29th, the,day on which John...iegal,s,Cookie Diet" was the second most popular s...
Other Medicine Technology:New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 2New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 3Sarah Palin, Dr. Siegal's Cookie Diet, and John McCain Top AOL Hot Searches List on August 29th 2
(Date:11/22/2009)...Variation can cause donated cells to attack recipi...Nov. 22 (HealthDay News) -- Researchers are report...boosts the risk that someone who,s had a bone-marr...raft-versus-host disease. , The immune system-... recipient has the variation and the donor does no...
(Date:11/22/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswi...following statement upon the United States Senate,...Health Care legislation: ,, "Senators Arlen Spe...hians and all Pennsylvanians for casting stand-up,...esident Obama,s historic Affordable Health Care Re...
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNew...90s to eliminate onchocerciasis (river blindness) ...alence of the disease in recent years, as evidence...equiring mass drug administration in six endemic c... annual meeting of the American Society of Tropica...
(Date:11/21/2009)... HAPPYneuron,s most popul...e on the iPhone and iPod Touch. , ...09 -- HAPPYneuron,s most popular and addictive gam...iPod Touch. Split Words is designed to help banish...he SplitWords iPhone brain game challenges the b...
(Date:11/20/2009)..., , PRINCETON, NJ, Nov. 20 /PRNewswire-Fir...today that a Special Meeting of Shareholders will ...of the Meeting is to consider approval of two spec...o approve and authorize the sale of all or substan... on the terms provided for in the asset purchase a...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3
...EW YORK, Aug. 13 Assurant, Inc. ("Assurant"),(NYS...ce and,insurance-related products and services, an...enior vice president, human resources, and Allen W...y,created., Both Ms. Meyer and Mr. Walker will co...
...DC says patients, doctors at fault for treatment g... WEDNESDAY, Aug. 13 (HealthDay News) -- About one ...e than one-third of those with epilepsy aren,t rec...rs among more than 120,000 adults in 19 states. ,...
... Consumers with hearing loss might think they are...-counter hearing aids, but they most likely will b...chasing such aids, according to MSU research. , ...al student from Denmark, published their study on ...
...EIJING, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- L...US) ("Lotus" or the,"Company"), a pharmaceutical c...today announced that it will conduct a conference ... and Chief Executive Officer of Lotus,Pharmaceutic...
...nnovative Program Blends New and Traditional Learn...ate Nursing Shortage, INDIANAPOLIS, Aug. 13 Orbi...aborative accelerated nursing program in the city ...,second program of its kind from Orbis, with the f...
... Scientists at the National Institutes of Health ... of mice that can lead to the development of autoi...ight on the processes that lead to the development... study paper appears online today in the journal ...
Other Medicine News:Health News:Assurant Announces Two Executive Appointments 2Health News:Epilepsy Receiving Inadequate Attention 2Health News:Study finds not all hearing aids are created equal 2Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: